by George Ciuciureanu | Oct 28, 2025 | Health, News
The U.S. FDA has granted Breakthrough Device Designation to SPINEstat® (14-3-3eta Autoantibody Multiplex Immunoassay Test), recognizing its potential to address a significant unmet need in the diagnosis of patients with axial spondyloarthritis (axSpA). SPINEstat®,...
by George Ciuciureanu | Oct 22, 2025 | Health, News
Vancouver, Canada – October 22, 2025 — Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA)....
by George Ciuciureanu | Jun 5, 2025 | Health, News
Take a Pain Check Foundation features a new blog highlighting Augurex’s 14-3-3eta biomarker. The blog post explores how biomarkers improve diagnosis and personalized care in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Vancouver, Canada – June 5,...
by George Ciuciureanu | Apr 22, 2025 | Health, News
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing...
by George Ciuciureanu | Apr 16, 2025 | Health, News
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune...
by George Ciuciureanu | Apr 1, 2025 | Health, News
Augurex is featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych, highlighting the role of 14-3-3eta across the RA care continuum. In this feature, Dr. Walter Maksymowych explores how 14-3-3eta helps close diagnostic and monitoring gaps in RA care....
